Cormorant Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
|
|||||
|
2024
Q1 | $23.5M | Sell |
|
|||||
|
2023
Q4 | $37.4M | Sell |
|
|||||
|
2023
Q3 | $76.1M | Buy |
|
|||||
|
2023
Q2 | $119M | Sell |
|
|||||
|
2023
Q1 | $89.7M | Sell |
|
|||||
|
2022
Q4 | $81.5M | Buy |
|
|||||
|
2022
Q3 | $101M | Buy |
|
|||||
|
2022
Q2 | $43M | Sell |
|
|||||
|
2022
Q1 | $57.2M | Buy |
|
|||||
|
2021
Q4 | $29.6M | Sell |
|
|||||
|
2021
Q3 | $30.5M | Buy |
|
|||||
|
2021
Q2 | $53.7M | Sell |
|
|||||
|
2021
Q1 | $80.1M | Hold |
|
|||||
|
2020
Q4 | $107M | Hold |
|
|||||
|
2020
Q3 | $56.3M | Sell |
|
|||||
|
2020
Q2 | $67.5M | Sell |
|
|||||
|
2020
Q1 | $60.7M | Sell |
|
|||||
|
2019
Q4 | $82.7M | Sell |
|
|||||
|
2019
Q3 | $71.7M | Buy |
|
|||||
|
2019
Q2 | $75.2M | Sell |
|
|||||
|
2019
Q1 | $70.2M | Sell |
|
|||||
|
2018
Q4 | $59.4M | Buy |
|
|||||
|
2018
Q3 | $74.2M | Sell |
|
|||||
|
2018
Q2 | $94.9M | Buy |
|
|||||
|
2018
Q1 | $90.4M | Buy |
|
|||||
|
2017
Q4 | $81.8M | Buy |
|